Notably, glucagon-like peptide-1 receptor agonists (GLP-1RAs), including widely used agents such as Ozempic, have demonstrated the ability to elevate adiponectin levels while improving metabolic and inflammatory profiles in patients with obesity and diabetes [35, 36]. This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.